Abstract
IntroductionGabapentinoids are among the most widely prescribed pain medications. However, there is growing evidence to suggest that gabapentinoids may be associated with dependence and misuse. The aim of this systematic review is to synthesise the qualitative literature on gabapentinoid misuse and symptoms of dependence. The findings of this study will inform efforts to mitigate emerging harms.Methods and analysisA systematic review of qualitative research will explore lived experiences of misuse and symptoms of dependence among people who use gabapentinoids. Six databases (MEDLINE, Scopus, Web of Science, CINAHL, EMBASE and PsycINFO) and grey literature sources will be searched from inception to May 2023. Qualitative studies that include people with lived experiences of gabapentinoid misuse and symptoms of gabapentinoid dependence will be included. Reference lists of included studies will also be screened for additional studies. The methodological quality of included studies will be appraised using the Critical Appraisal Skills Programme qualitative checklist, and higher quality studies will be prioritised in the thematic synthesis. The GRADE-CERQual approach will be used to assess confidence in the overall findings of the review.Ethics and disseminationEthical approval is not required for this systematic review. The findings of this review will be disseminated in peer-reviewed journals, at conferences and on social media.PROSPERO registration numberCRD42023401832.
Reference34 articles.
1. Gabapentinoid use in the United States 2002 through 2015;Johansen;JAMA Intern Med,2018
2. Trends in First Gabapentin and Pregabalin Prescriptions in Primary Care in the United Kingdom, 1993-2017
3. Pharmaceutical Benefits . PBSExpenditure and prescriptions report 1 July 2021 to 30 June 2022:department of health, . 2022 Available: https://www.pbs.gov.au/info/statistics/expenditure-prescriptions/pbs-expenditure-and-prescriptions
4. Pharmaceutical Benefits Scheme . expenditure and prescriptions twelve months to 30 June 2013. department of health. 2013. Available: https://www.pbs.gov.au/info/statistics/expenditure-prescriptions/pbs-expenditure-and-prescriptions
5. Alpha2Delta ligands, Gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use;Calandre;Expert Rev Neurother,2016